Abstract
Nearly all patients with metastatic prostate cancer will develop hormone-refractory disease that results in progressive clinical deterioration and ultimately death. Still today the choice of the best treatment for this neoplasm represents a challenge for geriatric oncologists. In this scenario a comprehensive geriatric assessment plays a key role. In fact, patients with a good performance status and without comorbidities may be suitable for a docetaxel-based and vinorelbine-based first and second line chemotherapy, respectively. On the contrary subjects with a poor performance status and with an ADL or IADL dependance can receive only a palliative treatment with the aim of preserve their quality of life.
Translated title of the contribution | Which therapy for elderly patients with hormone-refractory prostatic carcinoma? |
---|---|
Original language | Italian |
Pages (from-to) | 92-102 |
Number of pages | 11 |
Journal | Geriatric and Medical Intelligence |
Volume | 14 |
Issue number | 2 |
Publication status | Published - Jul 2005 |
ASJC Scopus subject areas
- Geriatrics and Gerontology